{
  "docId": "019de073-5c75-763a-a0f1-d995dc5da488",
  "docSlug": "01bee26c2c6ee992ec5e01a8e02dc689",
  "documentTitle": "Myovant Sciences | Results Presentation Deck | 34 slides",
  "authorId": "myovant-sciences",
  "authorName": "Myovant Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 34,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "appendix_disclosure",
  "function": "other",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Includes a disclaimer about the 24-month usage limit due to bone loss risk.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-5c75-763a-a0f1-d995dc5da488/10",
  "deckHref": "/decks/019de073-5c75-763a-a0f1-d995dc5da488",
  "deckJsonHref": "/decks/019de073-5c75-763a-a0f1-d995dc5da488.json",
  "deckAnchorHref": "/decks/019de073-5c75-763a-a0f1-d995dc5da488#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.43
      },
      "kind": "callout",
      "text": "Use of MYFEMBREE should be limited to 24 months due to the risk of continued bone loss which may not be reversible",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1023e4ae-9d56-4e35-9b39-b27b034b427f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "Full prescribing information for MYFEMBREE, including Black Box Warning, is available at www.myovant.com/myfembree-prescribing-information.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f124fae-3212-44bd-ae42-570beb199ffd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.25,
        "x": 0.7,
        "y": 0.2
      },
      "kind": "image",
      "text": "Product bottle image",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3670ef1-925e-489c-b474-ebf2f3826b17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "INDICATION: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. Management of moderate to severe pain associated with endometriosis in premenopausal women.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b790ed9-bc95-4c6c-96d3-a189800a50e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.57
      },
      "kind": "paragraph",
      "text": "DOSING: One tablet taken orally once daily, at approximately the same time each day, with or without food",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bc91668-d9e2-4065-8a2a-823435de447d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "DOSAGE FORM AND STRENGTH: Tablet containing a fixed-dose combination of relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d17c38c-1138-4e40-b88c-c4a8200414dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Overview of U.S. Prescribing Information for MYFEMBREE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a840242-34d0-4f08-adc1-9cba9497f372",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 16,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b061a9eb-90da-4016-a0fc-6239c295f0b9",
      "evidence": "The document presents data on the impact of MYFEMBREE on daily activities and pain relief",
      "position": 0,
      "objective": "Highlight the need for effective treatment options",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}